BeOne Medicines (ONC) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $124.8 million.
- BeOne Medicines' Net Income towards Common Stockholders rose 20287.68% to $124.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 10796.67%. This contributed to the annual value of -$644.8 million for FY2024, which is 2687.08% up from last year.
- Per BeOne Medicines' latest filing, its Net Income towards Common Stockholders stood at $124.8 million for Q3 2025, which was up 20287.68% from $94.3 million recorded in Q2 2025.
- BeOne Medicines' Net Income towards Common Stockholders' 5-year high stood at $215.4 million during Q3 2023, with a 5-year trough of -$590.7 million in Q4 2021.
- For the 5-year period, BeOne Medicines' Net Income towards Common Stockholders averaged around -$250.1 million, with its median value being -$348.4 million (2023).
- In the last 5 years, BeOne Medicines' Net Income towards Common Stockholders crashed by 75448.23% in 2022 and then surged by 20287.68% in 2025.
- Over the past 5 years, BeOne Medicines' Net Income towards Common Stockholders (Quarter) stood at -$590.7 million in 2021, then increased by 24.61% to -$445.3 million in 2022, then increased by 17.47% to -$367.6 million in 2023, then surged by 58.68% to -$151.9 million in 2024, then surged by 182.2% to $124.8 million in 2025.
- Its last three reported values are $124.8 million in Q3 2025, $94.3 million for Q2 2025, and $1.3 million during Q1 2025.